The Millisecond That Could Change Cancer Treatment – IEEE Spectrum

Report on FLASH Radiotherapy Development and Its Alignment with Sustainable Development Goals (SDGs)

Introduction

At the Swiss-French border, physicist Walter Wuensch oversees advanced particle accelerator technology at CERN, repurposed to develop FLASH radiotherapy—a revolutionary cancer treatment method. This initiative exemplifies the integration of cutting-edge physics with healthcare innovation, directly contributing to several United Nations Sustainable Development Goals (SDGs), notably SDG 3 (Good Health and Well-being) and SDG 9 (Industry, Innovation, and Infrastructure).

Background and Significance of FLASH Radiotherapy

1. Historical Context: Radiation therapy has been a fundamental cancer treatment since the discovery of X-rays in 1895. Conventional methods involve multiple low-dose sessions that risk damaging healthy tissue.
2. FLASH Radiotherapy Innovation: FLASH delivers ultrahigh-power radiation in less than a tenth of a second, significantly reducing harm to healthy tissue while maintaining tumor control.
3. Potential Impact: This technique promises stronger treatments with fewer side effects and increased accessibility, supporting SDG 3 by improving health outcomes and SDG 10 (Reduced Inequalities) by potentially expanding access to cancer care worldwide.

The Origin and Scientific Breakthrough of FLASH Therapy

• Initial Discovery: In the 1990s, Institut Curie researchers Vincent Favaudon and Marie-Catherine Vozenin observed that ultrafast, high-dose radiation did not cause expected lung fibrosis in mice.
• Experimental Expansion: Subsequent studies demonstrated that FLASH could eradicate tumors while sparing healthy tissue, overturning traditional radiotherapy trade-offs.
• Scientific Validation: Published findings in 2014 and subsequent studies confirmed FLASH’s efficacy across various tissues and species, fostering confidence in this novel approach.

Technological Adaptation for FLASH Radiotherapy

To translate FLASH into clinical practice, researchers addressed several technical challenges:

• Accelerator Development: Existing low-energy accelerators were insufficient for deep tumors; thus, high-energy linear accelerators capable of ultrafast, precise electron beam delivery were developed.
• Innovations at CERN and SLAC: CERN’s CLEAR facility and SLAC National Accelerator Laboratory contributed advanced accelerator technologies, enabling compact, efficient machines suitable for clinical settings.
• Engineering Challenges: Efforts focus on reducing size and power consumption to create hospital-compatible systems, aligning with SDG 9 by fostering sustainable industrial innovation.

Theryq’s Clinical Development Approach

1. Versatile Treatment Systems: Theryq is developing a range of FLASH devices targeting different tumor depths, including FLASHKNiFE for superficial tumors and FLASHDEEP for deep-seated tumors.
2. Integration of Imaging and Precision: Systems incorporate CT imaging and advanced patient positioning to ensure accurate, rapid treatment delivery.
3. Collaborative Efforts: Partnerships with CERN and clinical institutions exemplify multi-sector collaboration, supporting SDG 17 (Partnerships for the Goals).

Preclinical and Animal Testing Facilities

• Photo Injector Test Facility (PITZ): Located in Germany, PITZ provides a tunable accelerator and biomedical lab for systematic FLASH dose-rate studies and animal testing.
• Research Methodology: Studies progress from transparent zebra-fish embryos to mice, utilizing precise beam control and imaging to optimize treatment parameters.
• Technical Innovations: Development of new detectors to accurately measure ultrahigh dose rates addresses critical challenges in treatment safety and efficacy.

FLASH Radiotherapy as a Research and Societal Tool

Beyond treatment, FLASH offers unique opportunities to advance cancer biology understanding, potentially leading to novel therapies. Its ability to reduce treatment sessions can:

• Enhance global access to cancer care, particularly in low- and middle-income countries (supporting SDG 3 and SDG 10).
• Reduce healthcare costs and facility burdens in high-income countries.
• Foster collaborative research and innovation, contributing to SDG 9 and SDG 17.

Conclusion and Future Outlook

FLASH radiotherapy represents a transformative advancement in cancer treatment with significant alignment to the Sustainable Development Goals. While challenges remain, ongoing research, technological innovation, and international collaboration are paving the way for clinical adoption within the next decade. This progress underscores a commitment to improving global health outcomes, reducing inequalities, and promoting sustainable innovation.

1. Sustainable Development Goals (SDGs) Addressed or Connected

1. SDG 3: Good Health and Well-being
   • The article focuses on advancements in cancer treatment through FLASH radiotherapy, aiming to improve health outcomes and reduce side effects.
   • It highlights efforts to make cancer treatment more accessible and effective worldwide.
2. SDG 9: Industry, Innovation and Infrastructure
   • Development of advanced particle accelerators and medical technology for FLASH therapy demonstrates innovation in infrastructure and technology.
   • Collaboration between research institutions and companies to develop compact, efficient medical devices.
3. SDG 10: Reduced Inequalities
   • FLASH therapy’s potential to increase access to radiotherapy in low- and middle-income countries addresses health inequalities.
   • Reducing the burden of cancer treatment by enabling fewer sessions and lower costs.
4. SDG 17: Partnerships for the Goals
   • The article describes international collaboration among CERN, universities, hospitals, and companies to develop and implement FLASH therapy.

2. Specific Targets Under Those SDGs Identified

1. SDG 3: Good Health and Well-being
   • Target 3.4: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment.
   • Target 3.8: Achieve universal health coverage, including access to quality essential health-care services and access to safe, effective, quality, and affordable essential medicines and vaccines.
2. SDG 9: Industry, Innovation and Infrastructure
   • Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors, including encouraging innovation and increasing the number of research and development workers.
3. SDG 10: Reduced Inequalities
   • Target 10.2: Empower and promote the social, economic and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status.
4. SDG 17: Partnerships for the Goals
   • Target 17.6: Enhance North-South, South-South and triangular regional and international cooperation on and access to science, technology and innovation.

3. Indicators Mentioned or Implied to Measure Progress

1. Health Outcome Indicators
   • Reduction in tumor size and eradication rates in animal and human trials (implied through studies on mice, zebra fish, and human subjects).
   • Decrease in radiation-induced damage to healthy tissue, measured by tissue samples and scarring (e.g., fibrosis indicators).
   • Number of cancer patients receiving radiotherapy and improved survival rates (implied through increased access and effectiveness).
2. Technology and Innovation Indicators
   • Development and deployment of compact, high-energy linear accelerators capable of delivering FLASH therapy.
   • Number of clinical trials and phases completed for FLASH therapy devices.
   • Efficiency and precision metrics of accelerators (e.g., beam energy, dose rate, timing precision).
3. Access and Equity Indicators
   • Percentage of patients in low- and middle-income countries with access to radiotherapy.
   • Reduction in treatment sessions required per patient, lowering cost and travel burden.
4. Partnership and Collaboration Indicators
   • Number of international collaborations and partnerships established for FLASH therapy research and development.
   • Joint publications, patents, and technology transfers among institutions.

4. Table of SDGs, Targets, and Indicators

Source: spectrum.ieee.org